Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions

NCT00324116 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Degeneration

Interventions

DRUG: pegaptanib sodium (Macugen)

Sponsor

Pfizer

Collaborators

[object Object]